TEL-AML1 fusion RNA as a new target to detect minimal residual disease in pediatric B-cell precursor acute lymphoblastic leukemia

Blood

Volumn 88, Issue 1, 1996, Pages 302-308

  Cayuela, Jean Michel ^b   Baruchel, André ^b   Orange, Christine ^b   Madani, Ali ^b   Auclerc, Marie Françoise ^b   Daniel, Marie Thérese ^b   Schaison, Gérard ^b   Sigaux, François ^a  

^a SAINT LOUIS HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ASPARAGINASE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADULT; ARTICLE; B LYMPHOCYTE; BONE MARROW TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CHILD; CHROMOSOME 12; CHROMOSOME 21; CHROMOSOME TRANSLOCATION 12; FEMALE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROLYMPHOCYTE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030011272     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v88.1.302.bloodjournal881302     Document Type: Article

References (34)

1. Campana D, Pui CH: Detection of minimal residual disease in acute leukemia: Methodologic advances and clinical significance. Blood 85:1416, 1995
2. Beishuizen A, Verhoeven MAJ, van Wering ER, Hahlen K, Hooijkaas H, van Dongen JJM: Analysis of Ig and T-cell receptor genes in 40 childhood acute lymphoblastic leukemias at diagnosis and subsequent relapse: Implications for the detection of minimal residual disease by polymerase chain reaction analysis. Blood 83:2238, 1994
3. Steward CG, Goulden NJ, Katz F, Baines D, Martin PG, Langlands K, Potter MN, Chessels JM, Oakhill A: A polymerase chain reaction study of the stability of Ig heavy-chain and T-cell receptor δ gene rearrangements between presentation and relapse of child-hood B-Uneage acute lymphoblastic leukemia. Blood 83:1355, 1995
4. Baruchel A, Cayuela JM, Macintyre E, Berger R, Sigaux F: Assessment of clonal evolution at Ig/TCR loci in acute lymphoblastic leukemia by single-strand conformation polymorphism studies and highly resolutive PCR derived methods: Implication for a general strategy of minimal residual disease detection. Br J Haematol 85, 1995
5. Pui CH: Childhood leukemias. N Engl J Med 332:1619, 1995
6. Golub TR, Barker GF, Bohlander SK, Hiebert SW, Ward DC, Bray-Ward P, Morgan E, Raimondi SC, Rowley JD, Gilliland G: Fusion of TEL gene on 12p13 to the AML1 gene on 21q22 in acute lymphoblastic leukemia. Proc Natl Acad Sci USA 92:4917, 1995
7. Romana SP, Mauchauffe M, Le Coniat M, Chumakov I, Le Paslier D, Berger R, Bernard OA: The t(12;21) of acute lymphoblastic leukemia results in a tel-AML1 gene fusion. Blood 85:3662, 1995
8. Miyoshi H, Shimizu K, Kozu T, Maseki N, Kaneko Y, Ohki M: t(8;21) breakpoints on chromosome 21 in acute myeloid leukemia are clustered within a limited region of a single gene, AMLI. Proc Natl Acad Sci USA 88:10431, 1991
9. Wang S, Wang Q, Crute BE, Melnikova IN, Keller SR, Speck NA: Cloning and characterization of subunits of the T-cell receptor and murine leukemia virus enhancer core-binding factor. Mol Cell Biol 13:3324, 1993
10. Okuda T, van Deursen J, Hiebert SW, Grosveld G, Downing JR: AMLI, the target of multiple chromosomal translocations in human leukemia, is essential for normal fetal liver hematopoiesis. Cell 84:321, 1996
11. Golub TR, Barker GF, Lovett M, Gilliland DG: Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation. Cell 77:307, 1994
12. Romana SP, Le Coniat M, Berger R: t(12;21): A new recurrent translocation in acute lymphoblastic leukemia. Genes Chromosom Cancer 9:186, 1994
13. Chen Z, Sigaux F, Miglierina R, Valensi F, Daniel MT, Ochoa-Noguera MH, Flandrin G: Immunological typing of acute lymphoblastic leukemia: Concurrent analysis of flow cytofluorometry and immunocytology. Leuk Res 10:1411, 1986
14. Baruchel A, Leverger G, Schaison G, group for the FRALLE: Use of immunophenotype as part of the prognosis stratification for childhood ALL in the FRALLE 93 protocol. Leuk Lymphoma 91: 1994 (suppl 13)
15. Chomczynski P, Sacchi N: Single-step method of RNA isola-tion by acid guanidinium thiocyanate phenol-chloroform extraction. Anal Biochem 162:156, 1987
16. Sambrook J, Fritsch EF, Maniatis T: Molecular Cloning. A Laboratory Manual, Cold Spring Harbor, NY, Cold Spring Harbor Laboratory Press, 1989
17. Kwok S, Higuchi R: Avoiding false positives with PCR. Nature 339:237, 1989
18. Biondi A, Rambaldi A, Rossi V, Elia L, Caslini C, Basso G, Battista R, Barbui T, Mandelli F, Masera G, Croce C, Canaani E, Cimino G: Detection of ALL-1/AF4 fusion transcript by reverse transcription-polymerase chain reaction for diagnosis and monitoring of acute leukemias with the t(4;11) translocation. Blood 82:2943, 1993
19. Hunger SP, Galili N, Carroll AJ, Crist WM, Link MP, Cleary ML: The t(1; 19)(q23;p13) results in consistent fusion of E2A and PBX1 coding sequences in acute lymphoblastic leukemias. Blood 77:687, 1991
20. Kawasaki ES, Clark SS, Coyne MY, Smith SD, Champlin R, Witte ON, McCormick FP: Diagnosis of chronic myeloid and acute lymphoblastic leukemias by detection of leukemia-specific mRNA sequences amplified in vitro. Proc Natl Acad Sci USA 85:5698, 1988
21. Bernard O, Lecointe N, Jonveaux P, Souyri M, Mauchauffe M, Berger R, Larsen CJ, Mathieu-Mahul D: Two site-specific deletions and t(1;14) translocation restricted to human T-cell acute leukemias disrupt the 5′ part of the tal-1 gene. Oncogene 6:1477, 1991
22. Breit TM, Mol EJ, Wolvers-Tettero ILM, Ludwig WD, Van Wering ER, Van Dongen JJM: Site specific deletions involving the TALI and SIL genes are restricted to cells of the T cells of the T-cell receptor α/β lineage: T cell receptor δ gene deletion mechanism affect multiple genes. J Exp Med 177:965, 1993
23. Miyoshi H, Ohira M, Shimizu K, Mitani K, Hirai H, Imai T, Yokoyama K, Soeda E, Ohki M: Alternative splicing and genomic structure of the AML1 gene involved in acute myeloid leukemia. Nucleic Acids Res 23:2762, 1995
24. Romana SP, Poirel H, LeConiat M, Flexor MA, Mauchauffé M, Jonveaux P, Macintyre E, Berger R, Bernard OA: High frequency of t(12;21) in childhood B lineage acute lymphoblastic leukemia. Blood 86:4263, 1995
25. Shurtleff SA, Buijs A, Behm FG, Rubnitz JE, Raimondi SC, Hancock ML, Chan CGH, Pui CH, Grosveld G, Downing JR: TEL/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia 9:1985, 1995
26. Raynaud S, Cavé H, Baens M, Bastard C, Cacheux V, Grosgeorge J, Guidal-Giroux C, Guo C, Vilmer E, Marynen P, Grand-champ B: The 12; 21 translocation involving TEL and deletion of the other TEL allele: Two frequently associated alterations found in childhood acute lymphoblastic leukemia. Blood 1996 (in press)
27. Romana SP, LeConiat M, Poirel H, Marynen P, Bernard O, Berger R: Deletion of the short arm of chromosome 12 is a secondary event in acute lymphoblastic leukemia with t(12;21). Leukemia 10:167, 1996
28. Brisco MJ, Condon J, Hughes E, Neoh SH, Sykes PJ, Seshadri R, Toogood I, Waters K, Tauro G, Ekert H, Morley AA: Outcome prediction in childhood acute lymphoblastic leukemia by molecular quatitation of residual disease at the end of induction. Lancet 343:196, 1994
29. Cave H, Guidai C, Rohrlich P, Delfau MH, Broyart A, Lescoeur B, Rahimy C, Fenneteau O, Monplaisir N, d'Auriol L, Elion J, Vilmer E, Grandchamp B: Prospective monitoring and quantitation of residual blasts in childhood acute lymphoblastic leukemia by polymerase chain reaction study of delta and gamma T-cell receptor genes. Blood 83:1892, 1994
30. Seriu T, Yokata S, Nakao M, Misawa S, Takaue Y, Koizumi S, Kawai S, Fujimoto T: Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation. Leukemia 9:615, 1995
31. Steenbergen EJ, Verhagen OJHM, van Leeuwen EF, van der Berg H, Behrendt H, Slater RM, von dem Borne AEGKr, van der School CE: Prolonged persistence of PCR-detectable minimal residual disease after diagnosis or first relapse predicts poor outcome in childhood B-precursor acute lymphoblastic leukemia. Leukemia 9:1726, 1995
32. Wasserman R, Galili N, Ito Y, Silber JH, Reichard BA, Shane S, Womer RB, Lange B, Rovera G: Residual disease at the end of induction therapy as a predictor of relapse during therapy in child-hood B-lineage acute lymphoblastic leukemia. J Clin Oncol 10:1879, 1992
33. Nizet Y, Van Daele S, Lewalle P, Vaerman JL, Philippe M, Vermylen C, Cornu G, Ferrant A, Michaux JL, Martial P: Long-term follow-up of residual disease in acute lymphoblastic leukemia patients in complete remission using clonogenic IgH probes and the polymerase chain reaction. Blood 82:1618, 1993
34. O'Reilly J, Meyer B, Baker D, Hermann R, Cannell P, Davies J: Correlation of bone marrow minimal residual disease and apparent extramedullary relapse in childhood acute lymphoblastic leukemia. Leukemia 15:624, 1995